Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Yasmin Rosshandler, Ann Q Shen, Jorge Cortes, Hanna Jean Khoury

Journal: Expert review of hematology 2017;9(5):419-24

PMID: 26853281

Abstract

Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia.

Address: a Department of Hematology and Medical Oncology , the Winship Cancer Institute of Emory University, Emory University School of Medicine , Atlanta , GA , USA.; b Department of Leukemia , the University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.

DOI: 10.1586/17474086.2016.1151351